Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink

Key Points Question Are COVID-19 vaccines associated with Guillain-Barré syndrome (GBS)? Findings In this cohort study of surveillance data from the Vaccine Safety Datalink that included 15.1 million doses of COVID-19 vaccines, the unadjusted incidence rate of confirmed GBS in the 1 to 21 days after receiving the Ad.26.COV2.S (Janssen) vaccine was 32.4 per 100 000 person-years, which was significantly higher than the background rate of GBS. The unadjusted incidence rate of confirmed GBS in the 1 to 21 days after mRNA vaccines was 1.3 per 100 000 person-years, which did not differ from the background rate. Meaning These findings suggest an increased risk of GBS after Ad.26.COV2.S vaccination.

[1]  B. Bell,et al.  Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  M. Lunn,et al.  COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  Joshua T. B. Williams,et al.  Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems , 2021, Vaccine.

[4]  E. Woo,et al.  Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. , 2021, JAMA.

[5]  J. Gargano,et al.  Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[6]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[7]  Medha Tandon,et al.  A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination , 2021, Neurology international.

[8]  E. Woo,et al.  Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[9]  Esha Jain,et al.  Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine , 2021, Cureus.

[10]  H. Mangat,et al.  Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 Vaccine , 2021, Annals of neurology.

[11]  P. Tighe,et al.  Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination , 2021, Annals of neurology.

[12]  J. Gargano,et al.  Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[13]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[15]  Muhammad Zeeshan Shakir,et al.  Remote Condition Monitoring: A Prototype Based on Pycom Development Board FiPy and Pysense , 2019, 2019 UK/ China Emerging Technologies (UCET).

[16]  S. Sheikh,et al.  Guillain-Barré Syndrome Incidence in a Large United States Cohort (2000–2009) , 2012, Neuroepidemiology.

[17]  Ruihua Yin,et al.  H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. , 2011, American journal of preventive medicine.

[18]  Steven J. Jacobsen,et al.  The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety , 2011, Pediatrics.

[19]  Matthew Wise,et al.  Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[20]  J. Sejvar,et al.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.

[21]  E. Elm,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[22]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[23]  M Kulldorff,et al.  Spatial disease clusters: detection and inference. , 1995, Statistics in medicine.

[24]  OUP accepted manuscript , 2022, Brain.